- Home
- KRYS vs GNTX Comparison
KRYS vs GNTX Comparison
Compare KRYS & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRYS
- GNTX
- Stock Information
- Founded
- KRYS 2015
- GNTX 1974
- Country
- KRYS United States
- GNTX United States
- Employees
- KRYS N/A
- GNTX N/A
- Industry
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- GNTX Auto Parts:O.E.M.
- Sector
- KRYS Health Care
- GNTX Consumer Discretionary
- Exchange
- KRYS Nasdaq
- GNTX Nasdaq
- Market Cap
- KRYS 4.3B
- GNTX 4.8B
- IPO Year
- KRYS 2017
- GNTX N/A
- Fundamental
- Price
- KRYS $153.22
- GNTX $27.03
- Analyst Decision
- KRYS Strong Buy
- GNTX Buy
- Analyst Count
- KRYS 11
- GNTX 7
- Target Price
- KRYS $204.27
- GNTX $29.14
- AVG Volume (30 Days)
- KRYS 273.0K
- GNTX 2.8M
- Earning Date
- KRYS 08-04-2025
- GNTX 07-25-2025
- Dividend Yield
- KRYS N/A
- GNTX 1.75%
- EPS Growth
- KRYS 109.01
- GNTX N/A
- EPS
- KRYS 4.16
- GNTX 1.78
- Revenue
- KRYS $333,448,000.00
- GNTX $2,384,794,644.00
- Revenue This Year
- KRYS $40.10
- GNTX $7.38
- Revenue Next Year
- KRYS $49.73
- GNTX $7.17
- P/E Ratio
- KRYS $36.72
- GNTX $15.46
- Revenue Growth
- KRYS 247.53
- GNTX 2.43
- 52 Week Low
- KRYS $122.80
- GNTX $20.28
- 52 Week High
- KRYS $212.06
- GNTX $31.75
- Technical
- Relative Strength Index (RSI)
- KRYS 60.29
- GNTX 72.86
- Support Level
- KRYS $147.35
- GNTX $23.35
- Resistance Level
- KRYS $154.99
- GNTX $27.98
- Average True Range (ATR)
- KRYS 4.27
- GNTX 0.58
- MACD
- KRYS 0.11
- GNTX 0.46
- Stochastic Oscillator
- KRYS 69.85
- GNTX 82.21
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
About GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.